The opinion magazine of the American Gastroenterological Association
This is half of a two-part debate — read the opposing argument. Following the introduction of infliximab in 1998, two additional tumor necrosis factor antagonists (i.e., adalimumab, certolizumab pegol), the anti- integrin vedolizumab and ustekinumab (a monoclonal directed to interleukin 12 and 23) were approved for the management of inflammatory bowel disease. Biologics have greatly […]
This is half of a two-part debate — read the opposing argument. The safety and effectiveness of anti–tumor necrosis factor (TNF) therapy for the treatment of inflammatory bowel disease (IBD) has been well established for decades. Therefore, introducing anti-TNF biosimilars to the marketplace does not represent a new mode of treatment for patients with IBD, […]
Worldwide, idiosyncratic drug-induced liver injury (DILI) is an uncommon but important cause of acute and chronic liver disease. In general, the susceptibility of DILI is not related to the dose or duration of suspect medication use but rather has been attributed to novel host factors that may involve the individual patients’ microbiome, genome, or transcriptome.1 […]
Editor’s note: This feature originally appeared in The New Gastroenterologist. I have been a member of AGA since my first year of GI fellowship. Out of all the GI professional societies, I have always considered it to be my home. AGA is the organization I turn to for direction on providing high value and quality […]
AGA Research Foundation pilot awards are an invaluable tool for investigators, because they provide seed funding to explore promising new lines of research and generate preliminary data for larger grants. So, when David L. Boone, PhD, received the 2017 AGA-Pfizer Young Investigator Pilot Research Award in Inflammatory Bowel Disease from the AGA Research Foundation, he […]
Walled-off pancreatic necrosis (WON) is a defined entity that occurs following an episode of acute necrotizing pancreatitis. Direct endoscopic necrosectomy (DEN) is performed by advancing an endoscope transmurally into WON and has become an accepted modality. However, clinicians have many questions about endoscopic necrosectomy. Some of these questions will be addressed. 1. Is DEN required […]
Over the years there have been attempts at standardizing care for the patient with inflammatory bowel disease (IBD). I was the director of AGA’s initiative to establish quality metrics for the care of patients with IBD in 2011. Subramanian and Triadafilopoulos published a review in 2016,1 and Berry and Melmed published an excellent review this […]
I cannot think of many areas in medicine where there are more divergent opinions than in extraesophageal manifestations (EEMs) of gastroesophageal reflux disease (GERD). There are fervent believers and deniers, with frequent swings of the pendulum depending on the latest proposed mechanism and the tests used to support them. Furthermore, the long list of purported […]
The hospital is often the intersection between patients’ medical illness and their social and financial issues. As physicians, it is important to recognize that patient care encompasses the prescribing of medications, the performing of procedures as well as systems-based practice, and ensuring that social and financial barriers do not impede access to, and delivery of, […]
This is half of a two-part debate — read the opposing argument. Following the introduction of infliximab in 1998, two additional tumor necrosis factor antagonists (i.e., adalimumab, certolizumab pegol), the anti- integrin vedolizumab and ustekinumab (a monoclonal directed to interleukin 12 and 23) were approved for the management of inflammatory bowel disease. Biologics have greatly […]
Stay Connected